Management of atrial tachyarrhythmias. Rhythm control using implantable devices.
Presently, most devices with atrial diagnostic and therapeutic features are implanted in patients for electrical treatment of bradyarrhythmias and ventricular tachyarrhythmias. The painless electrical strategies for prevention and termination of ATa have not demonstrated significant clinical effectiveness in the general population with ATa. The effectiveness of ATP in reducing burden may be significantly higher in a subgroup of patients with a high incidence of stable ATa, but this needs to be evaluated prospectively. Smart sensing and detection schemes will also help provide accurate information and determine when ATa can be terminated with ATP. Although electrical defibrillation is effective, the discomfort associated with atrial shocks has limited the widespread use of this technology. Recent technological advances have increased the capabilities of implantable devices to store large amounts of diagnostic information. In the near future, implantable devices without transvenous leads may be implanted to monitor a variety of physiologic signals. This could help improve clinical outcomes and determine which therapies (pharmacologic, ablative, or electrical) would be most effective as well as monitor their safety and efficacy. Frequent monitoring from home and the availability of this data to the physician/nurse on the Internet can potentially improve the management of patients' ATa at a much lower cost.
Mehra
Rahul
R
Medtronic Inc., Minneapolis, Minnesota 55432, USA. rahul.mehra@medtronic.com
Ziegler
Paul
P
Sarkar
Shantanu
S
Ritscher
David
D
Warman
Eduardo
E
D001282:Atrial Flutter / Q000150:complications / Q000401:mortality / Q000628:therapy; D017147:Defibrillators, Implantable; D004554:Electric Countershock / Q000295:instrumentation / Q000379:methods; D006801:Humans; D010138:Pacemaker, Artificial; D013610:Tachycardia / Q000150:complications / Q000401:mortality / Q000628:therapy*; D017180:Tachycardia, Ventricular / Q000150:complications / Q000401:mortality / Q000628:therapy